In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 

Meet some of the people featured in the April 2017 issue of The Scientist.

Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.

Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.

Neoantigens may serve as valuable targets for new immunotherapies.